English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Adecade in development, Dendreon’s prostate cancer vaccine, sipuleucelT (Provenge), has become the first therapeutic cancer vaccine to receive approval from the U.S. Food and Drug Administration. The FDA approved Provenge in April to treat metastatic castration (hormone)-resistant prostate cancer. In the phase III trial, known as IMPACT, patients taking Provenge had a 4.1-month median improvement in overall survival. Although 4 months is a modest increase, some view Provenge’s approval as a milestone for the entire class of immunotherapeutic cancer vaccines. “Provenge’s approval is a watershed,” said

Approval of Provenge Seen As First Step for Cancer Treatment Vaccines